These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 35282455)
1. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Zhang Y; Liu X; Zhang H; Wang X Front Endocrinol (Lausanne); 2022; 13():836455. PubMed ID: 35282455 [TBL] [Abstract][Full Text] [Related]
2. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Tang X; Zhang H; Wang X; Yang D Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362 [TBL] [Abstract][Full Text] [Related]
3. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Sun L; Deng C; Gu Y; He Y; Yang L; Shi J Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J Front Immunol; 2022; 13():949746. PubMed ID: 36159792 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. Hu H; Wang J; Li X; Shen L; Shi D; Meng J Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959 [TBL] [Abstract][Full Text] [Related]
6. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. Shinozaki S; Tahara T; Lefor AK; Ogura M J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902 [TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. He K; Li J; Xi W; Ge J; Sun J; Jing Z Diabetes Res Clin Pract; 2022 Mar; 185():109791. PubMed ID: 35202771 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120 [TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679 [TBL] [Abstract][Full Text] [Related]
10. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557 [TBL] [Abstract][Full Text] [Related]
11. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Hadi A; Mohammadi H; Miraghajani M; Ghaedi E Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449 [No Abstract] [Full Text] [Related]
13. Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Wang LL; Zhang PH; Yan HH Front Nutr; 2023; 10():1014010. PubMed ID: 36866059 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Hu C; Qu T; Li L; Huang Y; Liu H; Rao C Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613 [TBL] [Abstract][Full Text] [Related]
15. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041 [TBL] [Abstract][Full Text] [Related]
16. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823 [TBL] [Abstract][Full Text] [Related]
17. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Stachowska E; Portincasa P; Jamioł-Milc D; Maciejewska-Markiewicz D; Skonieczna-Żydecka K Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187278 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial. Cai Y; Liang Q; Chen W; Chen M; Chen R; Zhang Y; Xiao Y; Chen L BMC Complement Altern Med; 2019 Jul; 19(1):178. PubMed ID: 31324247 [TBL] [Abstract][Full Text] [Related]
19. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. Goodarzi R; Sabzian K; Shishehbor F; Mansoori A Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Wang H; Wang L; Cheng Y; Xia Z; Liao Y; Cao J Biomed Rep; 2018 Jul; 9(1):90-96. PubMed ID: 29930810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]